Results 51 to 60 of about 80,161 (286)

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Turkish Journal of Internal Medicine, 2021
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Hayri Bostan, Erman Çakal   +4 more
doaj   +1 more source

Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection

British Journal of Pharmacology, 2022
Sodium glucose co‐transporter 2 inhibitors (SGLT‐2is) improve cardiovascular outcomes in both diabetic and non‐diabetic patients. Preclinical studies suggest that SGLT‐2is directly affect endothelial function in a glucose‐independent manner.
Xiaolin Li, B. Preckel, J. Hermanides, M. Hollmann, C. Zuurbier, N. Weber   +5 more
semanticscholar   +1 more source

Sodium-glucose transporter 2 inhibitors and their antiarrhythmic role: New insights and future perspective

Acta Marisiensis - Seria Medica
Sodium-glucose transporter 2 inhibitors have been identified as pleiotropic pharmacological agents with demonstrated efficacy in a wide range of pathologies.
Prația-Aron Diana-Ioana, Cozac Dan-Alexandru, Scridon Alina   +2 more
doaj   +1 more source

A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery

Acta Pharmaceutica Sinica B, 2013
The sodium/glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the kidney, and currently, SGLT2 inhibitors are considered as promising hypoglycemic agents for the treatment of type 2 diabetes mellitus.
Yi Huan, Linyi Li, Quan Liu, Shuainan Liu, Zhufang Shen   +4 more
doaj   +1 more source

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report

BMC Pharmacology and Toxicology, 2020
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose.
Miho Nakamura, Junya Nakade, Tadashi Toyama, Masaki Okajima, Takumi Taniguchi   +4 more
doaj   +1 more source

Discerning protein pools by selective staining with self‐labeling tags

FEBS Letters, EarlyView.
Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley   +1 more source

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors

International Journal of Molecular Sciences, 2022
Several recent cardiovascular trials of SGLT 2 (sodium-glucose cotransporter 2) inhibitors revealed that they could reduce adverse cardiovascular events in patients with T2DM (type 2 diabetes mellitus).
S. Dabravolski, A. Zhuravlev, A. Kartuesov, E. Borisov, V. Sukhorukov, A. Orekhov   +5 more
semanticscholar   +1 more source

Nutrient/TOR signaling controls adipose mitochondrial transcription factor A (TFAM) to regulate organismal growth in Drosophila

FEBS Letters, EarlyView.
Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas, Shahoon Khan, Abhishek Sharma, Byoungchun Lee, Savraj S. Grewal   +4 more
wiley   +1 more source

Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors

HYPERTENSION, 2020
Empaglifolzin, canagliflozin, and dapagliflozin are SGLT2 (sodium-glucose linked transporter type 2) inhibitors for treatment of type 2 diabetes mellitus that also reduce blood pressure, mortality, and cardiovascular disease and slow the loss of ...
C. Wilcox
semanticscholar   +1 more source

Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis

Diabetes, obesity and metabolism, 2023
To compare the relative efficacy of sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2is), glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and non‐steroidal mineralocorticoid receptor antagonists (nsMRAs) in improving the cardiovascular and renal ...
B. Nguyen, Le H. M. Nguyen, S. Mital, S. Bugden, Hai V. Nguyen   +4 more
semanticscholar   +1 more source